Please login to the form below

Not currently logged in
Email:
Password:

filgotinib

This page shows the latest filgotinib news and features for those working in and with pharma, biotech and healthcare.

EMA issues new guidance to limit use of JAK inhibitors for chronic inflammatory disorders

EMA issues new guidance to limit use of JAK inhibitors for chronic inflammatory disorders

This includes Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib).

Latest news

More from news
Approximately 3 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    Recently, Galapagos and Gilead Sciences received a positive NICE recommendation for Jyseleca (filgotinib) for use on the NHS which, for the first time, will support access to an advanced therapy for

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... If approved, filgotinib will be a late entrant into a very

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    filgotinib for rheumatoid arthritis. ... and filgotinib’s anticipated launch this year meets expectations in the increasingly competitive market for JAK inhibitors.

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis. ... This will include broader commercial rights in Europe for filgotinib, due to be filed later this year, setting up a 2020 launch.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest ... Likewise, upadacitinib will face competition

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...